GoodRx Holdings Inc

During thethree months ended December 31, 2024, other than as described below for Trevor Bezdek and Douglas

Hirsch, none of our directors or officers (as defined in Section 16 of the Exchange Act), adopted, modified orterminated any

contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative

defense conditions of Rule 10b5-1(c) of the Exchange Act (a "Rule 10b5-1 Trading Plan") or any "non-Rule 10b5-1 trading

arrangement" (as defined in Item 408(c) of Regulation S-K of the Exchange Act).

On December 16, 2024, Trevor Bezdek, our Co-Chairman and a director, and a grantor retained annuity trust, of which

Mr. Bezdek is the sole trustee and annuitant, early terminated their existing Rule 10b5-1 Trading Plan initially adopted on

June 7, 2024 for the sale of 5,391,994 shares of our Class A common stock, that was otherwise expected to remain in effect

until the earlier of (i) June 6, 2025, (ii) the date on which all trades set forth in such plan had been executed, or (iii) such time

as it was otherwise terminated according to its terms.

On December 16, 2024, Douglas Hirsch, a director, and a grantor retained annuity trust, of which Mr. Hirsch is the sole

trustee and annuitant, early terminated their existing Rule 10b5-1 Trading Plan initially adopted on June 7, 2024 for the sale

of 5,391,994 shares of our Class A common stock, that was otherwise expected to remain in effect until the earlier of (i) June

6, 2025, (ii) the date on which all trades set forth in such plan had been executed, or (iii) such time as it was otherwise

terminated according to its terms.